Trinity Biotech Plc Return on Equity

Trinity Biotech Plc (TRIB) currently reports a ROE of 51.99%. That is above the Healthcare sector average of 21.67%. Use the charts on this page to explore Trinity Biotech Plc's ROE history and peer comparisons.

Trinity Biotech Plc's ROE of 51.99% is higher than the Healthcare sector average of 21.67%. That is roughly 139.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Trinity Biotech Plc's current 51.99% should be judged against Healthcare norms (sector average: 21.67%) and against TRIB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 51.99%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Trinity Biotech Plc, and consider following TRIB for alerts when major investors trade the stock.

Trinity Biotech Plc is classified in the Healthcare sector. On ROE, it currently shows 51.99% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRIB with unrelated industries.